Genmab Income from Continuous Operations 2019-2024 | GMAB

Genmab income from continuous operations for the twelve months ending September 30, 2024 was $0.673B, a 6.2% increase year-over-year.

  • Genmab annual income from continuous operations for 2023 was $0.632B, a 19.18% decline from 2022.
  • Genmab annual income from continuous operations for 2022 was $0.782B, a 63.38% increase from 2021.
  • Genmab annual income from continuous operations for 2021 was $0.479B, a 34.35% decline from 2020.

Genmab Income from Continuous Operations 2019-2024 | GMAB

  • Genmab annual income from continuous operations for 2023 was $0.632B, a 19.18% decline from 2022.
  • Genmab annual income from continuous operations for 2022 was $0.782B, a 63.38% increase from 2021.
  • Genmab annual income from continuous operations for 2021 was $0.479B, a 34.35% decline from 2020.